4.0000 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||3.9700 x 900|
|Ask||4.0800 x 1200|
|Day's Range||3.9550 - 4.1600|
|52 Week Range||3.4300 - 6.9000|
|Beta (3Y Monthly)||1.46|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you're interested in Calithera Biosciences, Inc. (NASDAQ:CALA), then you might want to consider its beta (a measure...
PRESIDENT AND CEO of Calithera Biosciences Inc (NASDAQ:CALA) Susan Molineaux bought 51,600 shares of CALA on 06/25/2019 at an average price of $3.88 a share.
While Calithera Biosciences, Inc. (NASDAQ:CALA) shareholders are probably generally happy, the stock hasn't had...
Looking deeper into a target of a CRISPR deal, a fundraising for more-targeted approach to mental health therapies and more in our Health Care Digest.
Calithera, which develops novel small molecule therapies for cancer and other life-threatening diseases, announced positive top-line results from a Phase 2 study dubbed ENTRATA that is evaluating telaglenastat, or CB-839, in combination with the chemotherapy drug everolimus in patients with renal cell carcinoma. The enrollees demonstrated that the evaluated combo treatment doubled the median progress-free survival to 3.8 months compared to 1.9 months for everolimus alone, Calithera said. The risk of disease progression or death was also reduced by 36% in the combo treatment arm.
The South San Francisco, California-based company said it had a loss of 61 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Calithera (CALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of Calithera Biosciences, Inc. (NASDAQ:CALA) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller compa...
Calithera (CALA) initiates a phase I/II study of the glutaminase inhibitor, telaglenastat (CB-839) in combination with Pfizer's poly adenosine diphosphate ribose polymerase inhibitor, Talzenna.
In 2010 Susan Molineaux was appointed CEO of Calithera Biosciences, Inc. (NASDAQ:CALA). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...
Does the November share price for Calithera Biosciences Inc (NASDAQ:CALA) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by taking the expected future cash flows and Read More...
Calithera (CALA) delivered earnings and revenue surprises of -26.83% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 52 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
Calithera Biosciences Inc (NASDAQ:CALA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CALA Read More...